Back to Journals » Lung Cancer: Targets and Therapy » Volume 7

Modern management of malignant pleural mesothelioma

Authors patel S, Dowell J

Received 6 November 2015

Accepted for publication 17 January 2016

Published 3 May 2016 Volume 2016:7 Pages 63—72

DOI https://doi.org/10.2147/LCTT.S83338

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Jieming Gao

Peer reviewer comments 6

Editor who approved publication: Prof. Dr. Pan-Chyr Yang

Shivani C Patel,1 Jonathan E Dowell1,2

1Division of Hematology and Oncology, University of Texas Southwestern, 2Section of Hematology and Oncology, Veterans Affairs North Texas Healthcare System, Dallas, TX, USA

Abstract: Malignant pleural mesothelioma (MPM) is a deadly disease that produces a significant worldwide health care burden. The majority of cases are associated with prior asbestos exposure, but recent studies have identified a possible genetic predisposition in a minority of patients. Historically, obtaining a pathologic diagnosis of MPM was challenging, but with current pathological techniques, a secure diagnosis is possible in the majority of patients. Curative therapy for MPM remains elusive, and the primary treatment option for fit patients is platinum-based chemotherapy. Encouraging recent reports suggest that there may be a benefit to the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in MPM. Selected patients may be considered for aggressive surgical approaches, but there is considerable controversy regarding the true benefit of surgery and multimodality therapy in this disease.

Keywords: mesothelioma, asbestos, chemotherapy, surgery

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Readers of this article also read:

Stem cell technology in breast cancer: current status and potential applications

Chiotaki R, Polioudaki H, Theodoropoulos PA

Stem Cells and Cloning: Advances and Applications 2016, 9:17-29

Published Date: 26 April 2016

miRNA-21 as a novel therapeutic target in lung cancer

Markou A, Zavridou M, Lianidou ES

Lung Cancer: Targets and Therapy 2016, 7:19-27

Published Date: 2 March 2016

HSP90 as a novel molecular target in non-small-cell lung cancer

Esfahani K, Cohen V

Lung Cancer: Targets and Therapy 2016, 7:11-17

Published Date: 1 March 2016

Oncolytic viral therapy for pancreatic cancer: current research and future directions

Ady JW, Heffner J, Klein E, Fong Y

Oncolytic Virotherapy 2014, 3:35-46

Published Date: 17 February 2014

Update of research on the role of EZH2 in cancer progression

Shen L, Cui J, Liang S, Pang Y, Liu P

OncoTargets and Therapy 2013, 6:321-324

Published Date: 4 April 2013